Sven de Pourcq participates with a poster to EHA2024

In his poster, Sven presents his research on DNA methylation patterns in high-risk myelodysplastic syndrome (HR-MDS) patients undergoing oral azacitidine (AZA) therapy.

The study compares the demethylating effects of oral-AZA to subcutaneous (sc) AZA using Oxford Nanopore Technologies (ONT). Results indicate that oral-AZA shows comparable genome-wide demethylation to sc-AZA in most patients.

This research highlights ONT’s potential for monitoring therapeutic and disease-related DNA methylation changes, supporting its use in clinical settings to better understand and overcome AZA resistance in HR-MDS.

For more information, follow the link: EHA Library – The official digital education library of European Hematology Association (EHA) (ehaweb.org)